إعلان مُمول
Understanding the Modern Epilepsy Treatment Landscape

Epilepsy is a neurological disorder characterized by recurrent seizures which occur when clusters of nerve cells, or neurons, in the brain send out abnormal bursts of electrical energy. When neurons fire abnormally, it causes strange sensations, emotions, and behaviors or sometimes loss of consciousness. Epilepsy affects people of all ages. Anyone can develop epilepsy, but it's most common in young children and older adults. According to some estimations, epilepsy affects over 50 million people worldwide.
First Generation Anti-Epileptic Drugs
The first generation anti-epileptic drugs or Epilepsy Drugs were developed in the late 1800s and early 1900s. These AEDs include phenobarbital, primidone, phenytoin sodium, and carbamazepine. While these AEDs were a major step forward in epilepsy treatment when first introduced, they are now considered older drugs with significant side effects and drug interactions. Their mechanisms of action are also not fully understood. Phenobarbital, the oldest AED discovered in 1912, works by enhancing the effect of the neurotransmitter GABA, which inhibits brain cell activity. However, long-term use of phenobarbital is associated with sedation, behavioral changes, and cognitive impairment.
Second Generation AEDs Offers Improved Options
Starting in the 1990s, second generation AEDs were developed which offered improved tolerability over the first generation drugs. These include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide, and pregabalin. Many of these newer drugs have a better safety profile with fewer drug interactions and side effects. For example, lamotrigine and levetiracetam have a lower risk of cognitive problems or behavioral issues compared to phenobarbital. Second generation AEDs also target newer epilepsy mechanisms like voltage-gated ion channels and neurotransmitter receptors. This improved precision allows better seizure control with reduced adverse effects for many patients.
Get More Insights on- Epilepsy Drugs
الأقسام
إقرأ المزيد
The global scoliosis management market reached a value of USD 3060.51 million in 2023 and is expected to climb to USD 4188.52 million by 2031. This translates to a steady Compound Annual Growth Rate (CAGR) of 4% from 2024 to 2031. This press release explores the key factors influencing market growth, regional variations, and offers valuable takeaways for industry stakeholders. Key...

Air Canada Berlin Office: Your Gateway to Canada from Germany Air Canada Berlin Office plays a central role in bridging Germany’s vibrant capital with destinations across North America. As one of the airline’s primary service points in the region, this office offers comprehensive assistance to both seasoned travelers and first-time flyers. Whether you’re booking a business...
